Ulla Olsson-Strömberg

Granulocyte abundance and maturation state at diagnosis predicts treatment-free remission in CML

Purhonen, Mikko; Tatun, Mikael; Luukkainen, Katariina; Hung, Kevin et al.

Ingår i Leukemia, s. 2968-2977, 2025

• DOI för Granulocyte abundance and maturation state at diagnosis predicts treatment-free remission in CML
• Ladda ner fulltext (pdf) av Granulocyte abundance and maturation state at diagnosis predicts treatment-free remission in CML

Treatment-free remission after a second TKI discontinuation attempt in patients with Chronic Myeloid Leukemia re-treated with dasatinib: interim results from the DAstop2 trial

Flygt, Hjalmar; Söderlund, Stina; Richter, Johan; Saussele, Susanne et al.

Ingår i Leukemia, s. 781-787, 2024

• DOI för Treatment-free remission after a second TKI discontinuation attempt in patients with Chronic Myeloid Leukemia re-treated with dasatinib: interim results from the DAstop2 trial
• Ladda ner fulltext (pdf) av Treatment-free remission after a second TKI discontinuation attempt in patients with Chronic Myeloid Leukemia re-treated with dasatinib: interim results from the DAstop2 trial

Health-related quality of life and symptoms of chronic myeloid leukemia patients after discontinuation of tyrosine kinase inhibitors: results from the EURO-SKI Trial

Efficace, Fabio; Mahon, Francois-Xavier; Richter, Johan; Piciocchi, Alfonso et al.

Ingår i Leukemia, s. 1722-1730, 2024

• DOI för Health-related quality of life and symptoms of chronic myeloid leukemia patients after discontinuation of tyrosine kinase inhibitors: results from the EURO-SKI Trial

Management and outcome of patients with chronic myeloid leukemia in blast phase in the tyrosine kinase inhibitor era - analysis of the European LeukemiaNet Blast Phase Registry

Brioli, Annamaria; Lomaia, Elza; Fabisch, Christian; Sacha, Tomasz et al.

Ingår i Leukemia, s. 1072-1080, 2024

• DOI för Management and outcome of patients with chronic myeloid leukemia in blast phase in the tyrosine kinase inhibitor era - analysis of the European LeukemiaNet Blast Phase Registry
• Ladda ner fulltext (pdf) av Management and outcome of patients with chronic myeloid leukemia in blast phase in the tyrosine kinase inhibitor era - analysis of the European LeukemiaNet Blast Phase Registry

European Stop Tyrosine Kinase Inhibitor Trial (EURO-SKI) in Chronic Myeloid Leukemia: Final Analysis and Novel Prognostic Factors for Treatment-Free Remission

Mahon, Francois-Xavier; Pfirrmann, Markus; Dulucq, Stephanie; Hochhaus, Andreas et al.

Ingår i Journal of Clinical Oncology, 2024

• DOI för European Stop Tyrosine Kinase Inhibitor Trial (EURO-SKI) in Chronic Myeloid Leukemia: Final Analysis and Novel Prognostic Factors for Treatment-Free Remission

Granulocyte abundance and maturation state at diagnosis predicts treatment-free remission in CML

Purhonen, Mikko; Tatun, Mikael; Luukkainen, Katariina; Hung, Kevin et al.

Ingår i Leukemia, s. 2968-2977, 2025

• DOI för Granulocyte abundance and maturation state at diagnosis predicts treatment-free remission in CML
• Ladda ner fulltext (pdf) av Granulocyte abundance and maturation state at diagnosis predicts treatment-free remission in CML

Treatment-free remission after a second TKI discontinuation attempt in patients with Chronic Myeloid Leukemia re-treated with dasatinib: interim results from the DAstop2 trial

Flygt, Hjalmar; Söderlund, Stina; Richter, Johan; Saussele, Susanne et al.

Ingår i Leukemia, s. 781-787, 2024

• DOI för Treatment-free remission after a second TKI discontinuation attempt in patients with Chronic Myeloid Leukemia re-treated with dasatinib: interim results from the DAstop2 trial
• Ladda ner fulltext (pdf) av Treatment-free remission after a second TKI discontinuation attempt in patients with Chronic Myeloid Leukemia re-treated with dasatinib: interim results from the DAstop2 trial

Health-related quality of life and symptoms of chronic myeloid leukemia patients after discontinuation of tyrosine kinase inhibitors: results from the EURO-SKI Trial

Efficace, Fabio; Mahon, Francois-Xavier; Richter, Johan; Piciocchi, Alfonso et al.

Ingår i Leukemia, s. 1722-1730, 2024

• DOI för Health-related quality of life and symptoms of chronic myeloid leukemia patients after discontinuation of tyrosine kinase inhibitors: results from the EURO-SKI Trial

Management and outcome of patients with chronic myeloid leukemia in blast phase in the tyrosine kinase inhibitor era - analysis of the European LeukemiaNet Blast Phase Registry

Brioli, Annamaria; Lomaia, Elza; Fabisch, Christian; Sacha, Tomasz et al.

Ingår i Leukemia, s. 1072-1080, 2024

• DOI för Management and outcome of patients with chronic myeloid leukemia in blast phase in the tyrosine kinase inhibitor era - analysis of the European LeukemiaNet Blast Phase Registry
• Ladda ner fulltext (pdf) av Management and outcome of patients with chronic myeloid leukemia in blast phase in the tyrosine kinase inhibitor era - analysis of the European LeukemiaNet Blast Phase Registry

European Stop Tyrosine Kinase Inhibitor Trial (EURO-SKI) in Chronic Myeloid Leukemia: Final Analysis and Novel Prognostic Factors for Treatment-Free Remission

Mahon, Francois-Xavier; Pfirrmann, Markus; Dulucq, Stephanie; Hochhaus, Andreas et al.

Ingår i Journal of Clinical Oncology, 2024

• DOI för European Stop Tyrosine Kinase Inhibitor Trial (EURO-SKI) in Chronic Myeloid Leukemia: Final Analysis and Novel Prognostic Factors for Treatment-Free Remission

Single-cell analysis of immune recognition in chronic myeloid leukemia patients following tyrosine kinase inhibitor discontinuation

Huuhtanen, Jani; Adnan-Awad, Shady; Theodoropoulos, Jason; Forsten, Sofia et al.

Ingår i Leukemia, s. 109-125, 2024

• DOI för Single-cell analysis of immune recognition in chronic myeloid leukemia patients following tyrosine kinase inhibitor discontinuation
• Ladda ner fulltext (pdf) av Single-cell analysis of immune recognition in chronic myeloid leukemia patients following tyrosine kinase inhibitor discontinuation

The impact of Covid-19 in patients with chronic myeloid leukemia: a nationwide population-based study

Dahlen, Torsten; Flygt, Hjalmar; Lubking, Anna; Olsson-Strömberg, Ulla et al.

Ingår i Leukemia, s. 1156-1159, 2023

• DOI för The impact of Covid-19 in patients with chronic myeloid leukemia: a nationwide population-based study
• Ladda ner fulltext (pdf) av The impact of Covid-19 in patients with chronic myeloid leukemia: a nationwide population-based study

Characterization of the bone marrow niche in patients with chronic myeloid leukemia identifies CXCL14 as a new therapeutic option

Dolinska, Monika; Cai, Huan; Mansson, Alma; Shen, Jingyi et al.

Ingår i Blood, s. 73-89, 2023

• DOI för Characterization of the bone marrow niche in patients with chronic myeloid leukemia identifies CXCL14 as a new therapeutic option
• Ladda ner fulltext (pdf) av Characterization of the bone marrow niche in patients with chronic myeloid leukemia identifies CXCL14 as a new therapeutic option

Switching from imatinib to nilotinib plus pegylated interferon-α2b in chronic phase CML failing to achieve deep molecular response: clinical and immunological effects

Geelen, Inge G. P.; Gullaksen, Stein-Erik; Ilander, Mette M.; Olsson-Strömberg, Ulla et al.

Ingår i Annals of Hematology, s. 1395-1408, 2023

• DOI för Switching from imatinib to nilotinib plus pegylated interferon-α2b in chronic phase CML failing to achieve deep molecular response: clinical and immunological effects

Autologous hematopoietic stem cell transplantation significantly alters circulating ceramides in peripheral blood of relapsing-remitting multiple sclerosis patients

Vaivade, Aina; Wiberg, Anna; Khoonsari, Payam Emami; Carlsson, Henrik et al.

Ingår i Lipids in Health and Disease, 2023

• DOI för Autologous hematopoietic stem cell transplantation significantly alters circulating ceramides in peripheral blood of relapsing-remitting multiple sclerosis patients
• Ladda ner fulltext (pdf) av Autologous hematopoietic stem cell transplantation significantly alters circulating ceramides in peripheral blood of relapsing-remitting multiple sclerosis patients

Migrating to Long-Read Sequencing for Clinical Routine BCR-ABL1 TKI Resistance Mutation Screening

Schaal, Wesley; Ameur, Adam; Olsson-Strömberg, Ulla; Hermansson, Monica et al.

Ingår i Cancer Informatics, s. 1-8, 2022

• DOI för Migrating to Long-Read Sequencing for Clinical Routine BCR-ABL1 TKI Resistance Mutation Screening
• Ladda ner fulltext (pdf) av Migrating to Long-Read Sequencing for Clinical Routine BCR-ABL1 TKI Resistance Mutation Screening

Adverse outcomes in chronic myeloid leukemia patients treated with tyrosine kinase inhibitors: Follow-up of patients diagnosed 2002-2017 in a complete coverage and nationwide agnostic register study

Dahlen, Torsten; Edgren, Gustaf; Ljungman, Per; Flygt, Hjalmar et al.

Ingår i American Journal of Hematology, s. 421-430, 2022

• DOI för Adverse outcomes in chronic myeloid leukemia patients treated with tyrosine kinase inhibitors: Follow-up of patients diagnosed 2002-2017 in a complete coverage and nationwide agnostic register study
• Ladda ner fulltext (pdf) av Adverse outcomes in chronic myeloid leukemia patients treated with tyrosine kinase inhibitors: Follow-up of patients diagnosed 2002-2017 in a complete coverage and nationwide agnostic register study

IFN-alfa with dasatinib broadens the immune repertoire in patients with chronic-phase chronic myeloid leukemia

Huuhtanen, Jani; Ilander, Mette; Yadav, Bhagwan; Dufva, Olli M. J. et al.

Ingår i Journal of Clinical Investigation, 2022

• DOI för IFN-alfa with dasatinib broadens the immune repertoire in patients with chronic-phase chronic myeloid leukemia
• Ladda ner fulltext (pdf) av IFN-alfa with dasatinib broadens the immune repertoire in patients with chronic-phase chronic myeloid leukemia

Successful tyrosine kinase inhibitor discontinuation outside clinical trials - data from the population-based Swedish chronic myeloid leukaemia registry

Flygt, Hjalmar; Sandin, Fredrik; Dahlén, Torsten; Dremaine, Arta et al.

Ingår i British Journal of Haematology, s. 915-921, 2021

• DOI för Successful tyrosine kinase inhibitor discontinuation outside clinical trials - data from the population-based Swedish chronic myeloid leukaemia registry
• Ladda ner fulltext (pdf) av Successful tyrosine kinase inhibitor discontinuation outside clinical trials - data from the population-based Swedish chronic myeloid leukaemia registry

Long-term tolerability and efficacy after initial PegIFN-α addition to dasatinib in CML-CP: Five-year follow-up of the NordCML007 study

Flygt, Hjalmar; Söderlund, Stina; Stentoft, Jesper; Richter, Johan et al.

Ingår i European Journal of Haematology, s. 617-623, 2021

• DOI för Long-term tolerability and efficacy after initial PegIFN-α addition to dasatinib in CML-CP: Five-year follow-up of the NordCML007 study
• Ladda ner fulltext (pdf) av Long-term tolerability and efficacy after initial PegIFN-α addition to dasatinib in CML-CP: Five-year follow-up of the NordCML007 study

Molecular status 36 months after TKI discontinuation in CML is highly predictive for subsequent loss of MMR: final report from AFTER-SKI

Richter, Johan; Lübking, Anna; Söderlund, Stina; Lotfi, Kourosh et al.

Ingår i Leukemia, s. 2416-2418, 2021

• DOI för Molecular status 36 months after TKI discontinuation in CML is highly predictive for subsequent loss of MMR: final report from AFTER-SKI
• Ladda ner fulltext (pdf) av Molecular status 36 months after TKI discontinuation in CML is highly predictive for subsequent loss of MMR: final report from AFTER-SKI

Plasma proteomics of biomarkers for inflammation or cancer cannot predict relapse in chronic myeloid leukaemia patients stopping tyrosine kinase inhibitor therapy

Söderlund, Stina; Persson, Inger; Ilanderd, Mette; Guilhot, Joelle et al.

Ingår i Leukemia Research, 2020

• DOI för Plasma proteomics of biomarkers for inflammation or cancer cannot predict relapse in chronic myeloid leukaemia patients stopping tyrosine kinase inhibitor therapy

Bosutinib for pretreated patients with chronic phase chronic myeloid leukemia: primary results of the phase 4 BYOND study

Hochhaus, Andreas; Gambacorti-Passerini, Carlo; Abboud, Camille; Gjertsen, Bjørn Tore et al.

Ingår i Leukemia, s. 2125-2137, 2020

• DOI för Bosutinib for pretreated patients with chronic phase chronic myeloid leukemia: primary results of the phase 4 BYOND study
• Ladda ner fulltext (pdf) av Bosutinib for pretreated patients with chronic phase chronic myeloid leukemia: primary results of the phase 4 BYOND study

Profound but Transient Changes in the Inflammatory Milieu of the Blood During Autologous Hematopoietic Stem Cell Transplantation

Wiberg, Anna; Strömberg, Ulla Ohlsson; Herman, Stephanie; Kultima, Kim et al.

Ingår i Biology of blood and marrow transplantation, s. 50-57, 2020

• DOI för Profound but Transient Changes in the Inflammatory Milieu of the Blood During Autologous Hematopoietic Stem Cell Transplantation

Allogeneic stem cell transplantation for chronic myeloid leukemia in the TKI era: population-based data from the Swedish CML registry

Lubking, Anna; Dreimane, Arta; Sandin, Fredrik; Isaksson, Cecilia et al.

Ingår i Bone Marrow Transplantation, s. 1764-1774, 2019

• DOI för Allogeneic stem cell transplantation for chronic myeloid leukemia in the TKI era: population-based data from the Swedish CML registry

Immunological monitoring of newly diagnosed CML patients treated with bosutinib or imatinib first-line

Kreutzman, Anna; Yadav, Bhagwan; Brummendorf, Tim H.; Gjertsen, Bjorn Tore et al.

Ingår i Oncoimmunology, 2019

• DOI för Immunological monitoring of newly diagnosed CML patients treated with bosutinib or imatinib first-line
• Ladda ner fulltext (pdf) av Immunological monitoring of newly diagnosed CML patients treated with bosutinib or imatinib first-line

Prognosis of patients with chronic myeloid leukemia presenting in advanced phase is defined mainly by blast count, but also by age, chromosomal aberrations and hemoglobin

Lauseker, Michael; Bachl, Katharina; Turkina, Anna; Faber, Edgar et al.

Ingår i American Journal of Hematology, s. 1236-1243, 2019

• DOI för Prognosis of patients with chronic myeloid leukemia presenting in advanced phase is defined mainly by blast count, but also by age, chromosomal aberrations and hemoglobin
• Ladda ner fulltext (pdf) av Prognosis of patients with chronic myeloid leukemia presenting in advanced phase is defined mainly by blast count, but also by age, chromosomal aberrations and hemoglobin

Discontinuation of tyrosine kinase inhibitor therapy in chronic myeloid leukaemia (EURO-SKI): a prespecified interim analysis of a prospective, multicentre, non-randomised, trial

Saussele, Susanne; Richter, Johan; Guilhot, Joelle; Gruber, Franz X. et al.

Ingår i The Lancet Oncology, s. 747-757, 2018

• DOI för Discontinuation of tyrosine kinase inhibitor therapy in chronic myeloid leukaemia (EURO-SKI): a prespecified interim analysis of a prospective, multicentre, non-randomised, trial

Flow Cytometric Measurement of Blood Cells with BCR-ABL1 Fusion Protein in Chronic Myeloid Leukemia

Löf, Liza; Arngården, Linda; Olsson-Strömberg, Ulla; Siart, Benjamin et al.

Ingår i Scientific Reports, s. 1-9, 2017

• DOI för Flow Cytometric Measurement of Blood Cells with BCR-ABL1 Fusion Protein in Chronic Myeloid Leukemia
• Ladda ner fulltext (pdf) av Flow Cytometric Measurement of Blood Cells with BCR-ABL1 Fusion Protein in Chronic Myeloid Leukemia

Early BCR-ABL1 Transcript Decline after 1 Month of Tyrosine Kinase Inhibitor Therapy as an Indicator for Treatment Response in Chronic Myeloid Leukemia

El Missiry, Mohamed; Hjorth-Hansen, Henrik; Richter, Johan; Olsson-Strömberg, Ulla et al.

Ingår i PLOS ONE, 2017

• DOI för Early BCR-ABL1 Transcript Decline after 1 Month of Tyrosine Kinase Inhibitor Therapy as an Indicator for Treatment Response in Chronic Myeloid Leukemia
• Ladda ner fulltext (pdf) av Early BCR-ABL1 Transcript Decline after 1 Month of Tyrosine Kinase Inhibitor Therapy as an Indicator for Treatment Response in Chronic Myeloid Leukemia

Tyrosine kinase inhibitor therapy-induced changes in humoral immunity in patients with chronic myeloid leukemia

Rajala, Hanna L. M.; El Missiry, Mohamed; Ruusila, Anniina; Koskenvesa, Perttu et al.

Ingår i Journal of Cancer Research and Clinical Oncology, s. 1543-1554, 2017

• DOI för Tyrosine kinase inhibitor therapy-induced changes in humoral immunity in patients with chronic myeloid leukemia

KIT signaling is dispensable for human mast cell progenitor development

Dahlin, Joakim S.; Ekoff, Maria; Grootens, Jennine; Löf, Liza et al.

Ingår i Blood, s. 1785-1794, 2017

• DOI för KIT signaling is dispensable for human mast cell progenitor development

CLINICAL AND IMMUNOLOGICAL EFFECTS OF NILOTINIB IN COMBINATION WITH PEGYLATED INTERFERON-A2B IN PATIENTS WITH SUBOPTIMAL MOLECULAR RESPONSE ON IMATINIB (NORDDUTCHCML009)

Geelen, I.; Strömberg, Ulla Ohlsson; Mustjoki, S.; Richter, J. et al.

Ingår i Haematologica, s. 435-435, 2017

CHRONIC MYELOID LEUKEMIA PATIENTS WERE NOT DIFFERENT IN MOLECULAR RELAPSE AFTER STOPPING IMATINIB IN MR4 WHETHER RESIDUAL DISEASE WAS DETECTED OR NOT - WHEN ADJUSTING FOR NUMBER OF CONTROL TRANSCRIPTS

Pfirrmann, M.; Mahon, F-X; Guilhot, J.; Richter, J. et al.

Ingår i Haematologica, s. 153-153, 2017

Increased proportion of mature NK cells is associated with successful imatinib discontinuation in chronic myeloid leukemia.

Ilander, M; Olsson-Strömberg, Ulla; Schlums, H; Guilhot, J et al.

Ingår i Leukemia, s. 1108-1116, 2017

• DOI för Increased proportion of mature NK cells is associated with successful imatinib discontinuation in chronic myeloid leukemia.
• Ladda ner fulltext (pdf) av Increased proportion of mature NK cells is associated with successful imatinib discontinuation in chronic myeloid leukemia.

Advanced phase chronic myeloid leukaemia (CML) in the tyrosine kinase inhibitor era: a report from the Swedish CML register

Söderlund, Stina; Dahlén, Torsten; Sandin, Fredrik; Olsson-Strömberg, Ulla et al.

Ingår i European Journal of Haematology, s. 57-66, 2017

• DOI för Advanced phase chronic myeloid leukaemia (CML) in the tyrosine kinase inhibitor era: a report from the Swedish CML register

No increased prevalence of malignancies among first-degree relatives of 800 patients with chronic myeloid leukemia: a population-based study in Sweden

Gunnarsson, N.; Höglund, Martin; Stenke, L.; Sandin, F. et al.

Ingår i Leukemia, s. 1825-1827, 2017

• DOI för No increased prevalence of malignancies among first-degree relatives of 800 patients with chronic myeloid leukemia: a population-based study in Sweden

Leukotriene signaling via ALOX5 and cysteinyl leukotriene receptor 1 is dispensable for in vitro growth of CD34 (+)CD38(-) stem and progenitor cells in chronic myeloid leukemia

Dolinska, Monika; Piccini, Alexandre; Wong, Wan Man; Gelali, Eleni et al.

Ingår i Biochemical and Biophysical Research Communications - BBRC, s. 378-384, 2017

• DOI för Leukotriene signaling via ALOX5 and cysteinyl leukotriene receptor 1 is dispensable for in vitro growth of CD34 (+)CD38(-) stem and progenitor cells in chronic myeloid leukemia
• Ladda ner fulltext (pdf) av Leukotriene signaling via ALOX5 and cysteinyl leukotriene receptor 1 is dispensable for in vitro growth of CD34 (+)CD38(-) stem and progenitor cells in chronic myeloid leukemia

Single-cell transcriptomics uncovers distinct molecular signatures of stem cells in chronic myeloid leukemia

Giustacchini, Alice; Thongjuea, Supat; Barkas, Nikolaos; Woll, Petter S. et al.

Ingår i Nature Medicine, s. 692-+, 2017

• DOI för Single-cell transcriptomics uncovers distinct molecular signatures of stem cells in chronic myeloid leukemia

Single-cell molecular analysis defines therapy response and immunophenotype of stem cell subpopulations in CML

Warfvinge, Rebecca; Geironson, Linda; Sommarin, Mikael N. E.; Lang, Stefan et al.

Ingår i Blood, s. 2384-2394, 2017

• DOI för Single-cell molecular analysis defines therapy response and immunophenotype of stem cell subpopulations in CML

Plasma proteomics in CML patients before and after initiation of tyrosine kinase inhibitor therapy reveals induced Th1 immunity and loss of angiogenic stimuli

Söderlund, Stina; Christiansson, Lisa; Persson, Inger; Hjorth-Hansen, Henrik et al.

Ingår i Leukemia Research, s. 95-103, 2016

• DOI för Plasma proteomics in CML patients before and after initiation of tyrosine kinase inhibitor therapy reveals induced Th1 immunity and loss of angiogenic stimuli

Plasma Proteomics In Chronic Myeloid Leukemia Patients Before And After Initiation Of Tyrosine Kinase Inhibitor Therapy Reveals Induced Th1 Immunity And Loss Of Angiogenic Stimuli

Söderlund, Stina; Christiansson, Lisa; Persson, Inger; Hjorth-Hansen, H. et al.

Ingår i Haematologica, s. 730-730, 2016

In vivo CYP3A activity and pharmacokinetics of imatinib in relation to therapeutic outcome in chronic myeloid leukemia patients

Skoglund, Karin; Richter, Johan; Olsson-Strömberg, Ulla; Bergquist, Jonas et al.

Ingår i Therapeutic Drug Monitoring, s. 230-238, 2016

• DOI för In vivo CYP3A activity and pharmacokinetics of imatinib in relation to therapeutic outcome in chronic myeloid leukemia patients

Population-based assessment of chronic myeloid leukemia in Sweden: striking increase in survival and prevalence

Gunnarsson, Niklas; Sandin, Fredrik; Höglund, Martin; Stenke, Leif et al.

Ingår i European Journal of Haematology, s. 387-392, 2016

• DOI för Population-based assessment of chronic myeloid leukemia in Sweden: striking increase in survival and prevalence

Safety and efficacy of the combination of pegylated interferon-alpha 2b and dasatinib in newly diagnosed chronic-phase chronic myeloid leukemia patients

Hjorth-Hansen, H.; Stentoft, J.; Richter, J.; Koskenvesa, P. et al.

Ingår i Leukemia, s. 1853-1860, 2016

• DOI för Safety and efficacy of the combination of pegylated interferon-alpha 2b and dasatinib in newly diagnosed chronic-phase chronic myeloid leukemia patients

Pla Flow; A Flow Cytometry-Based Assay For Detection Of Bcr-Abl Fusion Protein In Blood Cells From Cml Patients

Löf, Liza; Olsson-Strömberg, Ulla; Landegren, Ulf; Kamali-Moghaddam, Masood

Ingår i Haematologica, s. 457-458, 2016

Assessment Of Therapy Response In Chronic Myeloid Leukemia Via 1 Month Bcr-Abl1 Transcript Decline

El Missiry, M.; Hjorth-Hansen, H.; Richter, J.; Olsson-Strömberg, Ulla et al.

Ingår i Haematologica, s. 63-63, 2016

Stopping Tyrosine Kinase Inhibitors In A Very Large Cohort Of European Chronic Myeloid Leukemia Patients: Results Of The Euro-Ski Trial

Richter, J.; Mahon, F. X.; Guilhot, J.; Hjorth-Hansen, H. et al.

Ingår i Haematologica, s. 22-23, 2016

Increased prevalence of prior malignancies and autoimmune diseases in patients diagnosed with chronic myeloid leukemia

Gunnarsson, N.; Höglund, Martin; Stenke, L.; Wallberg-Jonsson, S. et al.

Ingår i Leukemia, s. 1562-1567, 2016

• DOI för Increased prevalence of prior malignancies and autoimmune diseases in patients diagnosed with chronic myeloid leukemia

Assessment of bone marrow lymphocytic status during tyrosine kinase inhibitor therapy and its relation to therapy response in chronic myeloid leukaemia

El Missiry, Mohamed; Awad, Shady Adnan; Rajala, Hanna L.; Al-Samadi, Ahmed et al.

Ingår i Journal of Cancer Research and Clinical Oncology, s. 1041-1050, 2016

• DOI för Assessment of bone marrow lymphocytic status during tyrosine kinase inhibitor therapy and its relation to therapy response in chronic myeloid leukaemia

Cardiovascular Events Associated With Use of Tyrosine Kinase Inhibitors in Chronic Myeloid Leukemia: A Population-Based Cohort Study

Dahlen, Torsten; Edgren, Gustaf; Lambe, Mats; Höglund, Martin et al.

Ingår i Annals of Internal Medicine, s. 161-166, 2016

• DOI för Cardiovascular Events Associated With Use of Tyrosine Kinase Inhibitors in Chronic Myeloid Leukemia: A Population-Based Cohort Study

Clonal distribution of BCR-ABL1 mutations and splice isoforms by single-molecule long-read RNA sequencing

Cavelier, Lucia; Ameur, Adam; Häggqvist, Susana; Höijer, Ida et al.

Ingår i BMC Cancer, 2015

• DOI för Clonal distribution of BCR-ABL1 mutations and splice isoforms by single-molecule long-read RNA sequencing
• Ladda ner fulltext (pdf) av Clonal distribution of BCR-ABL1 mutations and splice isoforms by single-molecule long-read RNA sequencing

Evaluation of Intracellular Signaling Downstream Chimeric Antigen Receptors

Karlsson, Hannah; Svensson, Emma; Gigg, Camilla; Jarvius, Malin et al.

Ingår i PLOS ONE, 2015

• DOI för Evaluation of Intracellular Signaling Downstream Chimeric Antigen Receptors
• Ladda ner fulltext (pdf) av Evaluation of Intracellular Signaling Downstream Chimeric Antigen Receptors

The Tyrosine Kinase Inhibitors Imatinib and Dasatinib Reduce Myeloid Suppressor Cells and Release Effector Lymphocyte Responses

Christiansson, Lisa; Söderlund, Stina; Mangsbo, Sara; Hjorth-Hansen, Henrik et al.

Ingår i Molecular Cancer Therapeutics, s. 1181-1191, 2015

• DOI för The Tyrosine Kinase Inhibitors Imatinib and Dasatinib Reduce Myeloid Suppressor Cells and Release Effector Lymphocyte Responses

Dasatinib induces fast and deep responses in newly diagnosed chronic myeloid leukaemia patients in chronic phase: clinical results from a randomised phase-2 study (NordCML006)

Hjorth-Hansen, Henrik; Stenke, Leif; Söderlund, Stina; Dreimane, Arta et al.

Ingår i European Journal of Haematology, s. 243-250, 2015

• DOI för Dasatinib induces fast and deep responses in newly diagnosed chronic myeloid leukaemia patients in chronic phase: clinical results from a randomised phase-2 study (NordCML006)
• Ladda ner fulltext (pdf) av Dasatinib induces fast and deep responses in newly diagnosed chronic myeloid leukaemia patients in chronic phase: clinical results from a randomised phase-2 study (NordCML006)

Second malignancies following treatment of chronic myeloid leukaemia in the tyrosine kinase inhibitor era

Gunnarsson, Niklas; Stenke, Leif; Höglund, Martin; Sandin, Fredrik et al.

Ingår i British Journal of Haematology, s. 683-688, 2015

• DOI för Second malignancies following treatment of chronic myeloid leukaemia in the tyrosine kinase inhibitor era

FLOW CYTOMETRY-BASED ASSAY FOR DETECTION OF BCR-ABL FUSION PROTEIN IN BLOOD CELLS FROM CML PATIENTS

Löf, Liza; Olsson-Strömberg, Ulla; Landegren, Ulf; Kamali-Moghaddam, Masood

Ingår i Haematologica, s. 694-695, 2015

PROGRESSION OF CHRONIC PHASE CHRONIC MYELOID LEUKEMIA TO ADVANCED PHASE ON TKI THERAPY: A POPULATION BASED ANALYSIS FROM THE SWEDISH CML REGISTER

Söderlund, Stina; Dahlen, T.; Creignou, M.; Sandin, F. et al.

Ingår i Haematologica, s. 233-233, 2015

Bone Marrow Lymphocytic Status during Tyrosine Kinase Inhibitor Therapy and Its Relation to Therapy Response in Chronic Phase Chronic Myeloid Leukemia Patients

El Missiry, Mohamed; Adnan, Shady; Rajala, Hanna; Al-Samadi, Ahmed et al.

Ingår i Blood, 2015

Bone Marrow Lymphocytic Status during Tyrosine Kinase Inhibitor Therapy and Its Relation to Therapy Response in Chronic Phase Chronic Myeloid Leukemia Patients

El Missiry, Mohamed; Adnan, Shady; Rajala, Hanna; Al-Samadi, Ahmed et al.

Ingår i Blood, 2015

Safety and Efficacy of Addition of Pegylated Interferon alpha2b to Standard Dose Dasatinib in Newly Diagnosed Chronic Phase CML Patients

Hjorth-Hansen, Henrik; Stentoft, Jesper; Richter, Johan; Koskenvesa, Perttu et al.

Ingår i Blood, 2015

Mature, Adaptive-like CD56(DIM) NK Cells in Chronic Myeloid Leukemia Patients in Treatment Free Remission

Ilander, Mette; Schlums, Heinrich; Olsson-Strömberg, Ulla; Lahteenmaki, Hanna et al.

Ingår i Blood, 2015

Phenotypic and Functional Alterations of Bone Marrow Mesenchymal Stem and Progenitor Cells in Chronic Myeloid Leukemia

Dolinska, Monika; Klang, Johannis; Xiao, Pingnan; Durgaryan, Andranik et al.

Ingår i Blood, 2015

Increased Prevalence of Prior Malignancies and Autoimmune Diseases in Patients Diagnosed with Chronic Myeloid Leukemia

Gunnarsson, Niklas; Höglund, Martin; Stenke, Leif; Jonsson, Solveig Wallberg et al.

Ingår i Blood, 2015

The use of multiplex platforms for absolute and relative protein quantification of clinical material

Christiansson, Lisa; Mustjoki, Satu; Simonsson, Bengt; Olsson-Strömberg, Ulla et al.

Ingår i EuPA Open Proteomics, s. 37-47, 2014

• DOI för The use of multiplex platforms for absolute and relative protein quantification of clinical material

Antigen Signaling Enhances Proliferation and Cytotoxic Capacity of CD19-Targeting CD28/4-1BB CAR T Cells During Expansion Without Inducing Exhaustion

Karlsson, Hannah; Gigg, Camilla; Svensson, Emma; Larsson, Rolf et al.

Ingår i Molecular Therapy, 2014

CAR T Cells Express CD40L and Activates Human Dendritic Cells

Karlsson, Hannah; Gustafsson, Wictor; Olsson-Strömberg, Ulla; Savoldo, Barbara et al.

Ingår i Molecular Therapy, 2014

Disease Relapse After Tyrosine Kinase Inhibitor Treatment Discontinuation in Chronic Myeloid Leukaemia is Related to Both Low Number and Impaired Function of NK Cells

Ilander, Mette; Olsson-Strömberg, Ulla; Lahteenmaki, Hanna; Kasanen, Tiina et al.

Ingår i Scandinavian Journal of Immunology, s. 467-468, 2014

Musculoskeletal pain in patients with chronic myeloid leukemia after discontinuation of imatinib: a tyrosine kinase inhibitor withdrawal syndrome?

Richter, Johan; Söderlund, Stina; Lübking, Anna; Dreimane, Arta et al.

Ingår i Journal of Clinical Oncology, s. 2821-2823, 2014

• DOI för Musculoskeletal pain in patients with chronic myeloid leukemia after discontinuation of imatinib: a tyrosine kinase inhibitor withdrawal syndrome?

Interim Analysis of a Pan European Stop Tyrosine Kinase Inhibitor Trial in Chronic Myeloid Leukemia: The EURO-SKI study

Mahon, Francois-Xavier; Richter, Johan; Guilhot, Joelle; Muller, Martin C. et al.

Ingår i Blood, 2014

Early Disease Relapse after Tyrosine Kinase Inhibitor Treatment Discontinuation in CML Is Related Both to Low Number and Impaired Function of NK-Cells

Ilander, Mette Matilda; Olsson-Strömberg, Ulla; Lahteenmaki, Hanna; Tiina, Kasanen et al.

Ingår i Blood, 2014

Second Malignancies Following Treatment of Chronic Myeloid Leukemia in the Tyrosine Kinase Inhibitor Era

Gunnarsson, Niklas; Leif, Stenke; Höglund, Martin; Sandin, Fredrik et al.

Ingår i Blood, 2014

Increased Level of Myeloid-Derived Suppressor Cells, Programmed Death Receptor Ligand 1/Programmed Death Receptor 1, and Soluble CD25 in Sokal High Risk Chronic Myeloid Leukemia

Christiansson, Lisa; Söderlund, Stina; Svensson, Emma; Mustjoki, Satu et al.

Ingår i PLOS ONE, 2013

• DOI för Increased Level of Myeloid-Derived Suppressor Cells, Programmed Death Receptor Ligand 1/Programmed Death Receptor 1, and Soluble CD25 in Sokal High Risk Chronic Myeloid Leukemia
• Ladda ner fulltext (pdf) av Increased Level of Myeloid-Derived Suppressor Cells, Programmed Death Receptor Ligand 1/Programmed Death Receptor 1, and Soluble CD25 in Sokal High Risk Chronic Myeloid Leukemia

Impact of malignant stem cell burden on therapy outcome in newly diagnosed chronic myeloid leukemia patients

Mustjoki, S.; Richter, J.; Barbany, G.; Ehrencrona, H. et al.

Ingår i Leukemia, s. 1520-1526, 2013

• DOI för Impact of malignant stem cell burden on therapy outcome in newly diagnosed chronic myeloid leukemia patients

Enhanced proliferation and tyrosine kinase pathway engagement in 4-1BB domain-containing CAR T cells

Karlsson, H.; Svensson, E.; Lindqvist, C.; Hambardzumyan, K. et al.

Ingår i Human Gene Therapy, 2013

Tyrosine kinase inhibitor usage, treatment outcome, and prognostic scores in CML: report from the population-based Swedish CML registry

Höglund, Martin; Sandin, Fredrik; Hellstrom, Karin; Bjoreman, Mats et al.

Ingår i Blood, s. 1284-1292, 2013

• DOI för Tyrosine kinase inhibitor usage, treatment outcome, and prognostic scores in CML: report from the population-based Swedish CML registry

Combination of pegylated IFN-alpha 2b with imatinib increases molecular response rates in patients with low- or intermediate-risk chronic myeloid leukemia

Simonsson, Bengt; Gedde-Dahl, Tobias; Markevarn, Berit; Remes, Kari et al.

Ingår i Blood, s. 3228-3235, 2011

• DOI för Combination of pegylated IFN-alpha 2b with imatinib increases molecular response rates in patients with low- or intermediate-risk chronic myeloid leukemia

T regulatory cells control T-cell proliferation partly by the release of soluble CD25 in patients with B-cell malignancies

Lindqvist, Camilla A.; Christiansson, Lisa H.; Simonsson, Bengt; Enblad, Gunilla et al.

Ingår i Immunology, s. 371-376, 2010

• DOI för T regulatory cells control T-cell proliferation partly by the release of soluble CD25 in patients with B-cell malignancies

Molecular monitoring and mutation analysis of patients with advanced phase CML and Ph plus ALL receiving dasatinib

Olsson-Strömberg, Ulla; Hermansson, Monica; Lundan, Tuija; Ohm, Anne-Charlotte et al.

Ingår i European Journal of Haematology, s. 399-404, 2010

• DOI för Molecular monitoring and mutation analysis of patients with advanced phase CML and Ph plus ALL receiving dasatinib

Comparison of busulphan, hydroxyurea and allogeneic bone marrow transplantation (BMT) in chronic myeloid leukaemia: BMT prolongs survival

Olsson-Strömberg, Ulla; Simonsson, Bengt; Ahlgren, Tomas; Björkholm, Magnus et al.

Ingår i The Hematology Journal, s. 462-466, 2004

Safety of intratumoral immunostimulatory LOAd703 gene therapy in patients with advanced cancer

Irenaeus, Sandra; Wenthe, Jessica; Eriksson, Emma; Schiza, Aglaia et al.